NFE2L2 and cancer: Recent studies have shown that cancer cells can evade ferroptosis induced by SLC7A11 or GPX4 inhibition through activation of the NRF2-ARE pathway, and that inhibiting NRF2 may help overcome this resistance to ferroptotic cell death [195,196].